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Background. Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation. Cardiovascular-
related comorbidities are established to contribute to morbidity and mortality especially during exacerbations. The aim of the
current study was to determine alterations in hemorheology (erythrocyte aggregation, deformability) in newly diagnosed COPD
patients and their response to medical treatment and to compare with values of COPD patients with exacerbations.Materials and
Methods. The study comprised 13 COPD patients, 12 controls, and 16 COPD patients with exacerbations.The severity of COPDwas
determined according to Global Initiative for Chronic Obstructive Lung Disease guidelines. Red blood cell (RBC) deformability and
aggregation were measured by an ektacytometer. Results. RBC deformability of COPD patients with exacerbations was decreased
compared to the other groups. Erythrocyte aggregation and plasma fibrinogen of COPD patients determined during exacerbations
were higher than control. Conclusion. Decreased RBC deformability and increased aggregation associated with exacerbations
of COPD may serve as unfavorable mechanisms to worsen oxygenation and thus clinical symptoms of the patient. Treatment
modalities that modify rheological parameters might be beneficial.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a com-
mon, preventable, and manageable disease process that is
characterized by progressive persistent airflow restrictions
and related to increased chronic inflammatory reaction of
the airways and lungs against harmful gases and particles
[1]. Exacerbations of COPD are defined as the worsening of
symptoms such as increment of dyspnea, phlegm volume,
and phlegm purulence, usually accompanied by hypoxia and
hypercapnia [2, 3]. The most common causes of COPD exac-
erbations are infections. Inflammation is an important com-
ponent of the disease [4]. Macrophages and neutrophils play
an important role in the inflammatory process [5]. On the
other hand, RBCwere proposed as biosensors for the stadium
of COPD [6]. Nowadays, COPD treatment options include
quitting smoking, pharmacological treatment (short-acting
anticholinergic, short-acting beta2-agonist, long-acting anti-
cholinergic, long-acting beta2-agonist, and inhaled corti-
costeroids), and nonpharmacological treatment (pulmonary
rehabilitation) [7–9]. Aim of pharmacological treatment is
to improve the quality of life and exercise tolerance beside
achieving the reduction of symptoms and attacks [7, 8].
Inhaled corticosteroids specifically reduce the number of
COPD exacerbations [10]. In COPD exacerbation first of all,
it is important to identify the etiology. Viral and bacterial
infections, air pollution, and environmental factors can ini-
tiate COPD exacerbation. Thus, antibiotics and oral steroids
are choices of treatment [11].
Hemorheology is a branch of biorheology that focuses
on blood and its interactions in both macro- and microcir-
culation under the influence of the applied constraints [12].
Erythrocyte deformability, red blood cell (RBC) aggregation,
hematocrit (Hct), and blood viscosity are well-known com-
ponents of hemorheology [12–14]. The flow properties of
blood play significant roles in tissue perfusion.These proper-
ties are influenced by pathophysiological processes, including
a variety of pulmonary diseases, thereby increasing the
clinical relevance of blood rheology information [13, 15–17].
In COPDpatients, RBCwere shown to altermorphologically,
Hindawi
Canadian Respiratory Journal
Volume 2017, Article ID 1286263, 8 pages
https://doi.org/10.1155/2017/1286263
2 Canadian Respiratory Journal
like cytoskeleton changes, ultrastructural modifications, and
reductions of glycophorin A, band 3, and RBC thiols [7, 18,
19]. Rheological blood properties were demonstrated to pro-
gressively deteriorate as pulmonary insufficiency increases
in patients with chronic bronchitis [18]. There are limited
number of studies exploring hemorheological alterations in
COPD [16, 20–22]. The results of these studies were obtained
either from COPD patients at different stages of the illness
and age [18, 20, 22] or from patients receiving different types
of therapy (medication, exercise) [16, 20, 23]. Additionally,
different types ofmeasurement techniques, some being rather
old, were used in a variety of the studies mentioned above,
which makes it difficult to compare the results [20, 21, 24].
Thus, we aimed to determine the possible alterations in RBC
deformability and aggregation in newly diagnosed COPD
patients and their response to medical treatment and to
compare these parameters with values of COPDpatients with
exacerbations for the first time in the literature.The results of
the current study are expected to contribute to the formation
of alternative treatment options for COPD.
2. Materials and Methods
2.1. Subjects. Newly diagnosed patients with COPD as well as
COPD patients with exacerbations according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria at the Pulmonology Department of Pamukkale Uni-
versity were enrolled in the study. The severity of COPD
was evaluated by the GOLD, the American Thoracic Society,
and the European Respiratory Society. All subjects under-
went respiratory function testing performed with the patient
seated. Forced vital capacity (FVC), forced expiratory volume
in the first second (FEV1), forced expiratory flow 25% to
75% (FEF 25/75), and peak expiratory flow (PEF) were
measured with a clinical spirometer. We considered the
predicted percentage value of air exhaled during the first
second of forced expiration (pred FEV1%) and the Tiffeneau
index (FEV1/FVC). In particular, pulmonary function test
was evaluated in 13 newly diagnosed COPD patients before
and after 1 month of medical treatment and in 16 COPD
patients with exacerbations. The control group consisted of
12 subjects with comparable age and gender distribution.
Among these subjects who had hypoxia (oxygen saturation
≤ 97%) on a pulse oximeter reading applied via the finger,
smokers and patients with other systemic diseases were
excluded from the study. Patients with no obvious medical
problem were included in newly diagnosed group. COPD
exacerbation group consisted of severe and hospitalized
patients. FEV1/FVC < 70% with an expected FEV1 > 80%
indicates stage 1 (mild) of the disease process; 50% < FEV1 <
80% indicates stage 2 disease (moderate); 30% < FEV1 < 50%
indicates stage 3 disease (severe); and FEV1 < 30% indicates
stage 4 disease (most severe) [1]. After obtaining pretreatment
blood samples, patients were treated according to the stage
of the illness. Posttreatment blood samples were taken after 1
month of treatment. Although 40 newly diagnosed patients
were included in the beginning, 13 of them completed
the study. Ethical approval was obtained from Pamukkale
University Ethical Board on Human Experiments, with the
approval number 60116787-020/35881. All participants gave
their written informed consent to the study.
Treatment was in accordance with recently published
guidelines. Combination of short-acting beta2 agonists and/
or short-acting anticholinergics was applied to stage I COPD
patients, if necessary. Stage II patients were treated with
long-acting anticholinergics for 1month. COPDexacerbation
group received antibiotics and oral or IV steroids.
2.2. Samples and Measurements. Venous blood samples of
approximately 10mL were drawn by venipuncture after 8
hours of fasting. Blood samples containing EDTA (1000/cs,
100/cp) were appropriately transported to the physiology
laboratory and hemorheological tests were performed within
3 hours in accordance with “new guidelines for hemorheo-
logical laboratory techniques” [25]. Hematological parame-
ters as complete blood count were determined by an elec-
tronic hematology analyzer (Siemens ADVIA 2120i System,
Siemens Healthcare Diagnostics, Japan). Sodium citrated
blood samples were analyzed for plasma fibrinogen con-
centration using a fully automated coagulometer [Beckman
COULTER Acl top 700, instrumentation laboratory (USA)].
2.3. Erythrocyte DeformabilityMeasurements. RBC deforma-
bility was determined at various fluid shear stresses by laser
diffraction analysis using an ektacytometer (laser assisted
optical rotational cell analyzer (LORCA), RR Mechatronics,
Hoorn, Netherlands). The system has been described else-
where in detail [26]. Briefly, a low Hct suspension of RBC in
an isotonic viscous medium (4% polyvinylpyrrolidone 360
solution; MW 360 kD; Sigma P 5288; St. Louis, MI) was
sheared in a Couette system composed of a glass cup and
a precisely fitting bob, with a gap of 0.3mm between the
cylinders. A laser beam was directed through the sheared
sample, and the diffraction pattern produced by the deformed
cells was analyzed by a microcomputer. On the basis of the
geometry of the elliptical diffraction pattern, an elongation
index (EI) was calculated as EI = (𝐿 − 𝑊)/(𝐿 + 𝑊),
where 𝐿 and 𝑊 are the length and width of the diffraction
pattern, respectively. EI values were determined for 9 shear
stresses between 0.3 and 30 Pa and similar patterns of RBC
deformability alterations were obtained between groups at
all stress levels. All measurements were carried out at 37∘C.
Subsequently, the shear stress for half-maximal deformation
(SS1/2) was calculated using this nine-point data set for each
measurement by employing a Lineweaver–Burk analysis as
described elsewhere [27]. Briefly, the shear stress-EI curve
was linearized by plotting the reciprocal of EI as a function of
the reciprocal of shear stress: 1/EI = [(SS1/2/EImax)(I/SS)]+
1/EImax, where SS is shear stress and EImax is the theoretical
EI at infinite shear stress. The 𝑥-intercept of this line corre-
sponds to the negative reciprocal value of shear stress causing
half-maximal deformation (i.e., SS1/2); increased SS1/2 values
indicate decreased RBC deformability.
2.4. Erythrocyte Aggregation Measurements. RBC aggrega-
tion was also determined by LORCA as described elsewhere
[26]. The measurement is based on the detection of laser
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Hb (g/dl) 15.24 ± 1.75 15.54 ± 1.82 15.28 ± 1.51 13.57 ± 2.27𝛽 0.052 0.033
Hct (%) 44.95 ± 5.42 47.45 ± 6.17 45.78 ± 3.88 40.93 ± 6.35#,𝛽 0.013 0.045
RBC (m/𝜇L) 5.06 ± 0.61 5.21 ± 0.74 5.05 ± 0.55 4.57 ± 0.82 0.149 0.106
MCV (fL) 88.96 ± 3.73 91.41 ± 6.57 91.08 ± 5.81 90.13 ± 6.65 0.607 0.804
MCH (pg) 30.17 ± 0.97 29.98 ± 2.35 30.34 ± 2.07 29.83 ± 2.09 0.905 0.753
MCHC (g/dl) 33.95 ± 0.79 32.80 ± 1.07 33.32 ± 1.32 33.13 ± 1.41 0.060 0.246
WBC (K/uL) 7.41 ± 1.53 8.33 ± 1.85 8.66 ± 1.80 9.88 ± 5.40 0.228 0.231
Plt (K/uL) 214.64 ± 31.34 242.69 ± 49.77 242.38 ± 35.62 274.19 ± 154.62 0.263 0.175
Fibrinogen
(mg/dL) 321.18 ± 115.24 312 ± 86.57 292.27 ± 74.51 446.44 ± 193.65
∗,#,𝛽 0.014 0.005
RDW (%) 12.81 ± 0.77 13.99 ± 1.23 13.93 ± 1.34 15.18 ± 1.62∗,# 0.001 0.0001
Values are expressed as means ± SD (Hb: hemoglobin, Hct: hematocrit, RBC: red blood cell, MCV: mean corpuscular volume, MCH: mean corpuscular
hemoglobin, MCHC: mean corpuscular hemoglobin concentration, WBC: white blood cell, Plt: platelet count, and RDW: red blood cell distribution width).
𝑝1: difference between the control group, before treatment of newly diagnosed COPD, and the exacerbation group; 𝑝2: difference between the control group,
after treatment of newly diagnosed COPD, and the exacerbation group; ∗𝑝 < 0.05: difference from control, #𝑝 < 0.05: difference from before treatment of
COPD, and 𝛽𝑝 < 0.05: difference from after treatment of COPD.
backscattering from the sheared (disaggregated) and then
unsheared (aggregating) blood, performed in a computer-
assisted system at 37∘C. Backscattering data were evaluated
by the computer and the aggregation index (AI), aggregation
half time (𝑡1/2), and aggregation amplitude (AMP) were cal-
culated on the basis that there is less light backscattered from
aggregating red cells. Aggregation measurements were deter-
mined using RBC in autologous plasma adjusted to 40% Hct
and blood was fully oxygenated before the measurements.
2.5. Statistical Analyses. Continuous variables were ex-
pressed as mean ± standard deviation (SD), median (mini-
mum–maximumvalues), and categorical variables as number
and percent. Shapiro-Wilk tests were used for testing nor-
mality. If parametric test conditions were satisfied, Analysis
of Variance (ANOVA) was used for comparisons among
groups. The post hoc Tukey test was used when the ANOVA
determined a significant difference. If parametric test condi-
tions were not satisfied, the Kruskal-Wallis Variance Analysis
was used for comparisons among groups. The post hoc
Mann–Whitney𝑈 Test with Bonferroni Correction was used
when the Kruskal-Wallis Variance Analysis determined a sig-
nificant difference. For pairwise comparisons, if parametric
test conditions were satisfied, Paired Samples 𝑡-test was used
and if parametric test conditions were not satisfied,Wilcoxon
signed rank test was used. All statistical analyses were done by
SPSS 21.0. Power of the study was found to be over 95% with
95% confidence (𝛼 = 0.05).
3. Results
Table 1 shows the demographic characteristics and laboratory
data of the groups. The study enrolled 13 newly diagnosed
COPD patients (13 male) (mean age was 58.46 ± 9.72 years),
16 COPD patients with exacerbations (mean age was 67.75 ±
8.29 years), and 12 age and sex matched healthy controls
(12 male) (mean age was 54.16 ± 11.4 years) (𝑝 > 0.05).
The patients had a 48.8 ± 16.3 pack-years smoking history.
RDW of COPD patients during exacerbations was higher
compared to control and pretreatment of newly diagnosed
patients groups (𝑝 = 0.0001 and 𝑝 = 0.039, resp.), whereas
fibrinogen level of this group was higher than all the other
groups (𝑝 < 0.05). Additionally, Hb of COPDpatients during
exacerbations was less than posttreatment group (𝑝 = 0.05)
and Hct of these patients were lower compared to both pre-
and posttreatment groups (𝑝 = 0.003 and 𝑝 = 0.05, resp.).
There was no other statistically significant alteration between
the parameters demonstrated in Table 1 (𝑝 > 0.05).
Table 2 shows pulmonary function test results of the
subjects. Mean baseline predicted value of FEV1, FEV1/FVC,
PEF, and FEF 25/75 of control group were significantly higher
than COPD patients (𝑝 < 0.05). The treatment applied in
newly diagnosed patients did not cause statistically signifi-
cant alterations in pulmonary function test results. FVC (𝑝 =
0.001), FEV1, FEV1/FVC, and FEF 25/75 (𝑝 = 0.0001) of
COPD patients with exacerbations were lower than control
group while PEF of these patients were decreased compared
to both control group andCOPDpatients receiving treatment
(𝑝 = 0.0001 and 𝑝 = 0.031, resp.).
Erythrocyte deformability (i.e., the elongation index, EI)
for the RBC of the experimental groups was measured at
nine shear stresses between 0.3 and 30.0 pascal (Pa) and
shown in Table 3. RBC deformability of COPD patients
with exacerbations measured at 0.53–30.00 Pa was decreased
compared to control. On the other hand, EI of the same group
measured at 0.30–9.49 Pa was lower than COPD patients
receiving treatment (𝑝 < 0.05).
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Table 2: Pulmonary function test results of the subjects.
Pulmonary function test Control group(𝑛 = 12)
Newly diagnosed
patient group Exacerbation group






FVC (%) 97.67 ± 14.07 82.23 ± 13.97 88.77 ± 16.10 68.5 ± 30.63∗ 0.005 0.006
FEV1 (%) 99.25 ± 12.83 66.69 ± 13.83∗ 75.54 ± 20.14∗ 64.36 ± 16.10∗ 0.0001 0.0001
FEV1/FVC ratio 82.58 ± 6.04 63.85 ± 4.71∗ 64.46 ± 8.66∗ 60.93 ± 8.13∗ 0.0001 0.0001
PEF (%) 90.33 ± 12.06 64.69 ± 16.12∗ 70.54 ± 24.56∗ 46.88 ± 29.38∗,𝛽 0.0001 0.0001
FEF 25–75 (%) 90.67 ± 20.83 35.38 ± 9.40∗ 42.08 ± 14.51∗ 25.38 ± 16.20∗ 0.0001 0.0001
Values are expressed as means ± SD (FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, PEF: peak expiratory flow, and FEF 25/75:
forced expiratory flow 25% to 75%). 𝑝1: difference between the control group, before treatment of newly diagnosed COPD, and the exacerbation group; 𝑝2:
difference between the control group, after treatment of newly diagnosed COPD, and the exacerbation group; ∗𝑝 < 0.05: difference from control, #𝑝 < 0.05:
difference from before treatment of COPD, and 𝛽𝑝 < 0.05: difference from after treatment of COPD. 𝑝1 and 𝑝2 are findings via ANOVAwhereas other symbols
are findings by comparison of two groups.













0.30 0.06 ± 0.03 0.06 ± 0.02 0.05 ± 0.02 0.04 ± 0.01# 0.039 0.333
0.53 0.12 ± 0.05 0.12 ± 0.05 0.08 ± 0.04 0.05 ± 0.01∗,# 0.010 0.001
0.95 0.21 ± 0.08 0.21 ± 0.08 0.17 ± 0.057 0.12 ± 0.02∗,# 0.002 0.001
1.69 0.33 ± 0.10 0.31 ± 0.09 0.26 ± 0.07 0.22 ± 0.02∗,# 0.002 0.001
3.00 0.41 ± 0.07 0.40 ± 0.08 0.36 ± 0.06 0.32 ± 0.02∗,# 0.001 0.001
5.33 0.49 ± 0.05 0.47 ± 0.06 0.45 ± 0.06 0.42 ± 0.02∗,# 0.001 0.001
9.49 0.55 ± 0.04 0.54 ± 0.05 0.51 ± 0.05 0.50 ± 0.02∗,# 0.001 0.003
16.87 0.60 ± 0.04 0.59 ± 0.04 0.57 ± 0.04 0.55 ± 0.02∗ 0.006 0.002
30.00 0.63 ± 0.04 0.63 ± 0.04 0.61 ± 0.04 0.59 ± 0.02∗ 0.007 0.017
Values are expressed as means ± SD; EI: elongation index and Pa: pascal. 𝑝1: difference between the control group, before treatment of newly diagnosed COPD,
and the exacerbation group; 𝑝2: difference between the control group, after treatment of newly diagnosed COPD, and the exacerbation group;
∗𝑝 < 0.05:
difference from control, #𝑝 < 0.05: difference from before treatment of COPD, and 𝛽𝑝 < 0.05: difference from after treatment of COPD. 𝑝1 and 𝑝2 are findings
via ANOVA whereas other symbols are findings by comparison of two groups.
Table 4 demonstrates that EImax and SS1/2 of the exac-
erbation group were statistically significantly higher than the
other groups (𝑝 < 0.05).
Erythrocyte aggregation parameters (AI and 𝑡1/2) are
demonstrated in Table 5. AI (𝑝 = 0.0001) of COPD patients
determined during exacerbations was higher whereas 𝑡1/2
(𝑝 = 0.001) was lower compared to control group. Increment
of AI is in concordance with decrement of 𝑡1/2 and indicates
augmentation of RBC aggregation.
4. Discussion
COPD is a leading cause of mortality and morbidity with
increasing prevalence worldwide [28, 29]. It is a progressive
condition characterized by a poorly reversible airflow limi-
tation associated with an abnormal inflammatory response
of the lung. There is evidence that, in different lung dis-
eases, including COPD, blood cells may undergo distinct
alterations. Erythrocytes are affected at different levels in
COPD, including structural alterations [23, 30]. Further-
more, emerging themes in RBC biology support the new
concept that erythrocytes are also signalling cells [31, 32], with
important roles in the regulation of biochemical interactions
with other cells in (patho) physiology. Hypoxia is one of
the prognostic factors in COPD [21]. Tissue oxygenation
depends on three factors: (1) the functional integrity of the
pulmonary, cardiac, and vascular system, (2) the quantity and
quality of the hemoglobin molecule and binding of oxygen
to hemoglobin, and (3) the flow characteristics of the blood
(hemorheology) [33, 34]. Blood flow, RBC aggregation, and
deformability are main components of hemorheology. In the
microcirculation, RBCmust collapse to pass through narrow
capillaries; hence, RBC deformability and aggregation are
major determinants of resistance to flow. The ability of the
entire RBC to deform is critically important to perform its
function of oxygen delivery and is also a determinant of cell
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(𝑛 = 13) Exacerbation group
(𝑛 = 16) 𝑝1 𝑝2Before treatment After treatment
EImax 0.64 ± 0.21 0.68 ± 0.24 0.66 ± 0.37 0.83 ± 0.15∗,#,𝛽 0.001 0.0001
SS1/2 2.06 ± 1.29 3.16 ± 3.65 4.64 ± 7,92 6.17 ± 3.3∗,#,𝛽 0.0001 0.0001
Values are expressed as means ± SD; EImax: theoretical EI at infinite shear stress and SS1/2: shear stress at half-maximal deformation. 𝑝1: difference between
the control group, before treatment of newly diagnosed COPD, and the exacerbation group; 𝑝2: difference between the control group, after treatment of newly
diagnosed COPD, and the exacerbation group; ∗𝑝 < 0.05: difference from control, #𝑝 < 0.05: difference from before treatment of COPD, and 𝛽𝑝 < 0.05:
difference from after treatment of COPD. 𝑝1 and 𝑝2 are findings via ANOVA whereas other symbols are findings by comparison of two groups.
Table 5: The RBC aggregation measurements of the groups.
Control group
(𝑛 = 12)
Newly diagnosed patient group
Exacerbation group
(𝑛 = 16) 𝑝1 𝑝2Before treatment(𝑛 = 13)
After treatment
(𝑛 = 13)
AMP (au) 25.0 ± 2.91 25.1 ± 3.90 24.65 ± 3.18 20.77 ± 3.59∗,#,𝛽 0.002 0.002
AI (%) 68.15 ± 5.90 72.33 ± 6.16 73.16 ± 8.17 79.96 ± 3.61∗ 0.0001 0.007
𝑡1/2 (sn) 1.79 ± 0.55 1.45 ± 0.55 1.39 ± 0.68 1.01 ± 0.37∗ 0.001 0.003
Values are expressed as means ± SD; AMP: amplitude of aggregation; AI: aggregation index; 𝑡1/2: aggregation half time. 𝑝1: difference between the control
group, before treatment of newly diagnosed COPD, and the exacerbation group; 𝑝2: difference between the control group, after treatment of newly diagnosed
COPD, and the exacerbation group; ∗𝑝 < 0.05: difference from control, #𝑝 < 0.05: difference from before treatment of COPD, and 𝛽𝑝 < 0.05: difference from
after treatment of COPD.
survival time in the circulation [35, 36]. RBC aggregation is
a reversible process meaning a temporary linear or branched
aggregate formation of the erythrocytes under critically low
shear stress conditions. The physiological importance of
erythrocyte aggregation which is the reversible adhesion of
adjacent erythrocytes in circulation is its tendency to increase
the blood viscosity in low shear flow and to disturb the
passage in capillary circulation [37, 38].
Current study demonstrates hemorheological parameters
(i.e., RBC deformability and aggregation) in newly diagnosed
stage 1-2 COPD patients and the alterations in these param-
eters in response to one-month medical treatment and com-
pares these parameters with values of COPD patients during
acute exacerbations. RDW of COPD patients during exacer-
bations was increased, andHb andHct decreased as expected
[39, 40]. No statistically significant alteration was observed
in deformability of the RBC of the newly diagnosed exper-
imental groups measured at nine shear stresses between 0.3
and 30.0 Pa as well as Elmax and SS1/2 values. Similar to our
results, Karul et al. found no difference in osmotic fragility
of stable COPD patients compared to controls [21]. On the
other hand, Coppola et al. measured erythrocyte filterability
in 15COPDpatients of 67–79 years old and found it decreased
[20]. Santini et al. demonstrated an increase in membrane
rigidity in erythrocytes of COPD patients with respect to
controls. According to the authors, this increase in red cell
rigiditymight be due to enhanced sphingomyelin values [30].
Index of RBC deformability was also found to be decreased
in chronic cor pulmonale decompensation [18, 22]. The
disparity in RBC deformability results seems to be due to the
technique used, age of the patients, severity of the disease, and
the presence of complications. LORCA (laser assisted optical
rotational cell analyzer) which is an up-to-date device to
measure RBCdeformability and aggregationwith a good rep-
etition of consecutive measurements was used in our study.
Results of the current study demonstrate for the first time
in the literature that RBC deformability of COPD patients
with exacerbations is lower than both healthy subjects (at
0.53–30.00 Pa) and newly diagnosed COPD patients receiv-
ing treatment (at 0.30–9.49 Pa). It was mentioned before that
impaired RBC deformability leads to increased SS1/2 values.
The shear stress level of normal pulmonary circulation was
demonstrated to be around 2-3 Pa [41]. This information
increases the importance of the reduced RBC deformability
determined at 1.69 and 3 Pa in COPD exacerbations, herein.
When EImax and SS1/2 values were evaluated, erythrocyte
deformability of the COPD patients with exacerbations was
also found to be lower compared to COPD patients before
treatment. These reports support the suggestion that presen-
tation and comparison of data via this approach may pro-
vide a more comprehensive view of RBC stress-deformation
behavior compared to shear stress-EI curves since it utilizes
the entire range of shear stress [27]. The relations between
pressure and blood flow becomemore complex in the micro-
circulation as the vessel diameter approaches average RBC
size [42]. In addition to the existing lung pathology, decreased
RBC deformability in COPD patients during exacerbations
may serve as an unfavorable factor to worsen the clinical con-
dition of the patient by further disrupting tissue oxygenation.
Another hemorheological parameter measured in our
study is the RBC aggregation. The aggregation index (AI)
and aggregation half time (𝑡1/2) of newly diagnosed COPD
patients were not different from healthy subjects. One month
of appropriate treatment did not cause any statistically signif-
icant alteration in the aggregation parameters of the patients
nor the FVC, PEF, and FEV1/FVC ratio. AI of COPD patients
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with exacerbations was higher whereas 𝑡1/2 was lower than
healthy subjects. Increment of AI is in concordance with
decrement of 𝑡1/2 and indicates augmentation of RBC aggre-
gation. Similarly, Osipova et al. evaluated hemorheological
properties by spontaneous aggregation of erythrocytes and
observed a concurrently higher aggregation of erythrocytes
in patients with COPD. The rheological blood properties
worsened as hypertension of the small blood-circulation
circle was increasing [43]. Index of RBC aggregation was
found to increase in chronic cor pulmonale decompensation
[18, 22]. Functional disturbances of erythrocytes in chronic
bronchitis patients were shown to aggravate the course of the
disease and need correction with membrane-stabilizing and
membrane-repairing drugs [15, 18]. Plasma fibrinogen level
is known as one of the most important determinants of RBC
aggregation. The tendency to aggregate increases as fibrino-
gen concentration rises [34]. Thus, increased fibrinogen level
observed in our COPD exacerbation group may provide an
explanation for the augmentation of RBC aggregation in this
group. Additionally, although not determined in our study,
increases in plasma levels of inflammatory cytokines IL-6
and IL-8 were demonstrated in acute exacerbations of COPD
[44] which may also alter RBC aggregation. It is also worth
noting here that, in addition to decreased RBC deformability,
increment of erythrocyte aggregation in COPD patients with
exacerbation may also further play a role in diminishing
circulation.
Oxidative stress represents one of the key mechanisms
in the development of COPD [45]. Numerous studies have
shown that oxidative stress is increased in lungs and systemic
circulation of patients with COPD [46–50]. Markers of
oxidative stress were found to increase even further during
exacerbations of COPD [51] and in patients with very severe
form of this disease [52]. Some studies have also demon-
strated a marked decrease in plasma antioxidant capacity
of COPD patients, while other studies have shown opposite
findings [53]. RBC mechanical properties (i.e., erythrocyte
deformability and aggregation) are known to be altered
in response to oxidative stress [54, 55]. Although possible
changes in oxidative stress parameters were not investigated
in our study, due to the above information, it can be spec-
ulated here that impaired hemorheology herein may at least
partly be due to increased oxidative stress in these patients.
5. Conclusion
In overview, the results of the current study indicate that
exacerbations of COPD are characterized by significant
hemorheological abnormalities known to adversely affect
blood flow. The decrement observed in RBC deformability
and the increment shown in erythrocyte aggregation during
exacerbations might complement other pathophysiologic
mechanisms, leading to worsening of oxygenation and thus
clinical symptoms. The mechanisms of the hemorheological
alterations could not be clarified. Oxidative stress and inflam-
mation may be involved. Therapeutic approaches including
antioxidants for normalizing hemorheological parameters
during exacerbations of COPD may also be recommended.
However, whether therapies to decrease RBC aggregation and
enhance deformability directly and specifically can be devel-
oped and whether such therapies will relieve the patient’s
symptoms remain an area of active investigation. Further
researchwith a larger number of patients to explain themech-
anisms of hemorheological alterations may be necessary.
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[40] E. Günay, S. Sarinç Ulaşli, O. Akar et al., “Neutrophil-to-
lymphocyte ratio in chronic obstructive pulmonary disease: a
retrospective study,” Inflammation, vol. 37, no. 2, pp. 374–380,
2014.
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